Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KLA578-1
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First-in-Human Single and Multiple Dose of KLA578-1 for Injection
Details : KLA578-1 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2025
Lead Product(s) : KLA578-1
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tagitanlimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Akeso
Deal Size : Undisclosed
Deal Type : Agreement
Akeso Received Payment for the Development Collaboration on Tagitanlimab
Details : Under the terms of the agreement, Sichuan Kelun is reponsible for the development of KL-A167 (tagitanlimab), antibody targeting PD-L1, following its recent marketing approval by China's NMPA.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : Tagitanlimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Akeso
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SKB571
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $37.5 million
Deal Type : Licensing Agreement
Merck & Co. Buys Kelun ADC For $37.5M, Drops Another Asset
Details : Merck has taken up its option on SKB571, a bispecific ADC that Kelun sees primarily as a treatment of solid tumors such as lung cancer and gastrointestinal tumors.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : SKB571
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $37.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $9,475.0 million
Deal Type : Collaboration
Details : Under the agreement, Kelun-Biotech has granted Merck global licenses to research, develop, manufacture and commercialize multiple investigational preclinical Antibody Drug Conjugate therapies for treating cancer and additional licenses to ADC candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $175.0 million
December 22, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $9,475.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Merck & Co
Deal Size : $936.0 million
Deal Type : Collaboration
Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD
Details : Under the terms of the agreement, Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational Antibody Drug Congugate (ADC) for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $35.0 million
July 26, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Merck & Co
Deal Size : $936.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : $1,407.0 million
Deal Type : Licensing Agreement
China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland’s Merck Sharp & Dohme
Details : The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $47.0 million
May 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : $1,407.0 million
Deal Type : Licensing Agreement
Lead Product(s) : A166
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Levena Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : A166
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Levena Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Gefitinib Tablets Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 11, 2017
Reset All
